Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,900 shares, a decrease of 27.5% from the August 31st total of 4,000 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is currently 0.5 days.

Advaxis Stock Up 2.3 %

ADXS opened at $2.21 on Friday. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $44.80. The firm has a market cap of $4.00 million, a price-to-earnings ratio of -22.05 and a beta of 2.07. The stock has a 50-day simple moving average of $3.23.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Advaxis in a research report on Monday, August 22nd. They set a "sell" rating on the stock.

About Advaxis

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Recommended Stories

• Get a free copy of the StockNews.com research report on Advaxis (ADXS)
• Humana Proves Vertically Integrated Healthcare Works
• What Cintas Can Teach Investors About This Bear Market?
• 2 Casino Stocks Worth Taking a Look At
• This Small-Cap Healthcare Name Is Outperforming Its Index
• Blackberry Stock Declines As Results Come In Lukewarm Once Again

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.